CD274 and Sepsis: Third, early-phase clinical trials of PD-1/PD-L1 blockade in sepsis have so far involved small cohorts and primarily assessed immunological surrogates (e.g., restoration of ex vivo cytokine production) rather than hard clinical endpoints such as mortality or long-term functional recovery [95,96,97].